Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Secures New U.S. Patent for Its EVM301 Series of Drug Candidates

March 31, 2026

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2025

March 27, 2026

Enveric Biosciences Announces Registration of Five Trademarks

March 18, 2026

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

February 25, 2026

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

February 19, 2026

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

January 29, 2026

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 28, 2026

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

January 28, 2026

Enveric Biosciences Announces Patent Issuance

December 29, 2025

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

December 12, 2025

1
2
3
…
19
›

Company

Team

Psybrary™

Pipeline

Investors

Contact

Sign Up for Updates

© 2026 Enveric Biosciences | Terms of Use | Privacy Policy

Enveric Biosciences is a development stage company that markets no products at this time. The content of this site is not intended to be promotional or to suggest any product or use of a product that has been approved by any regulatory body.